Navigation Links
Spheris Reports Fourth Quarter and Year-End 2007 Results
Date:3/26/2008

quately protect our intellectual property rights, including our proprietary technology and the intellectual property we license from third parties.

The Company takes no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release.

SPHERIS INC.

Condensed Consolidated Statements of Operations

(Amounts in Thousands)

(Unaudited)

Three Months ended December 31, Year ended December 31,

2007 2006 2007 2006

Net revenues $48,597 $51,375 $200,392 $207,141

Operating expenses:

Direct costs of

revenues (exclusive

of depreciation and

amortization below) 35,290 37,343 144,094 152,120

Marketing and selling

expenses 1,026 1,377 4,781 5,392

General and

administrative

expenses 4,953 4,558 19,892 18,974

Depreciation and

amortization 6,101 6,840 24,273 26,553

Total operating

costs 47,370 50,118 193,040 203,039

Operating

income 1,227 1,257 7,352 4,102

Loss on refinance

of debt - - 1,828 -

Interest expense,

net 5,038 5,487 21,171 21,136

Other expense

(income) 1,240 (261) 1,570 (401)

Net loss before

income taxes
'/>"/>

SOURCE Spheris
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Spheris Sets Fourth Quarter 2007 Earnings Release and Conference Call Dates
2. Spheris Elects New Board Member
3. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
4. QMed, Inc. Reports Year-End and Fourth Quarter Results
5. Pelosi Statement on Social Security and Medicare Trustees Reports
6. NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports
7. SPO Medical Reports 2007 Sales: Growth of 35% Compared to 2006
8. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
9. U.S. Army Study Reports WoundStat(TM) is Most Effective
10. CryoCor Reports 2007 Results
11. IPC The Hospitalist Company Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Allscripts (Nasdaq: MDRX ... financial results for the three and six months ... opens on Monday, January 11, 2010. Allscripts management ... discuss the company,s earnings and other information at ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts ...
(Date:12/16/2009)... Averting second, possibly deadly, attack is long-term goal, researchers ... Researchers have developed a tool to predict whether a ... of a first stroke. , "This is an important ... have a second stroke soon after a first stroke ... Dr. Hakan Ay, of Massachusetts General Hospital and Harvard ...
(Date:12/16/2009)... at work on a malaria elimination study in Africa ... the disease using cell phone records. , The scientists ... often residents of Zanzibar travel and where they go. ... coast of Tanzania in East Africa, Zanzibar has drastically ... study as part of deliberations on whether to launch ...
(Date:12/16/2009)... has been found, , , WEDNESDAY, Dec. 16 (HealthDay News) ... to food poisoning and the stomach pain and diarrhea ... some urinary tract infections. , Researchers have found the ... and restaurants and in women with the infections. ... directly to the women through the food they ate, ...
(Date:12/16/2009)... 8 percent of children are uninsured, government report finds ... first six months of this year, 45.4 million Americans ... population -- had no health insurance, according to new ... addition, 58.4 million (19.4 percent) people of all ages ... year prior to the interview, and 31.9 million (10.6 ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Scientists use cell phone records to predict spread of malaria 2Health News:Scientists use cell phone records to predict spread of malaria 3Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Over 45 Million Americans Now Lack Health Insurance 2
... cell line from a lifeless human embryo. Ethical issues ... developing naturally//. ,The study and ... embryonic stem cells has raised ethical concerns due to ... ,Researcher Miodrag Stojkovic said, "The study shows ...
... BOSTON - The Journal of Sexual Medicine has published the ... for treatment in patients with erectile dysfunction (ED). The study ... vardenafil // and sildenafil treatment in men with ED and ... more efficient and patients showed preference for the use of ...
... Center has become the first hospital in the ... surgery//, which doctors believe will change the standard ... the Hybrid OR/Cath Lab, the state-of-the-art operating suite ... to perform open-heart surgeries, like coronary bypass, as ...
... is cheap, ART — assisted reproductive technology — is ... effect on the treatments pursued by infertile couples in ... income makes a difference in whether they pursue an ... and insurance coverage also have a strong impact on ...
... prevalence of contagious skin infections, the threat of pandemic ... and Detergent Association (SDA) to issue its second Clean ... from 2004, when the country received a “C.” ... that clean hands save lives,” said Nancy Bock, SDA ...
... Mayo Clinic Proceedings says that regardless of the claims ... inherent risk of bloodstream infections in hospitalized adult patients. ... the bloodstream, but the catheter is the most commonly ... infections occur in the United States each year and ...
Other Medicine News:Health News:Patients suffering ED happy with Vardenafil drugs 2Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 2Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 3Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 4Health News:Money Matters When Choosing an Infertility Treatment 2Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 2Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 3Health News:Infection Risk High With All IVDs 2
(Date:12/16/2009)... Verathon®, maker of BladderScan® bladder volume instruments ... volume ultrasound is now included in the ... of Catheter-Associated Urinary Tract Infections (CA-UTIs). ... November 2009, replace the previous guidelines which ... are located on the Web at: ...
(Date:12/16/2009)... Ga., Dec. 16 Greenway Medical Technologies, ... electronic health record (EHR), practice management and interoperability ... in KLAS" awards in the annual 2009 ... & Professional Services report. ,, For practices ... Chart was named Best in KLAS in ...
(Date:12/16/2009)... BioSpecifics Technologies Corp. (Nasdaq: BSTC ... collagenase-based products, today announced top-line efficacy and safety ... XIAFLEX(TM) for the treatment of Peyronie,s disease. Peyronie,s ... collagen on the shaft of the penis, which ... difficult or impossible in advanced cases. The Phase ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4Nanosensors Spot Early Signs of Cancer 63194 1Nanosensors Spot Early Signs of Cancer 63194 2Scripps Research scientists crack mystery of proteins dual function 11127 1Scripps Research scientists crack mystery of proteins dual function 11127 2Scripps Research scientists crack mystery of proteins dual function 11127 3How to Attack Holiday Stress Head On 63191 1How to Attack Holiday Stress Head On 63191 2
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR ... that it has entered into a $400,000 common stock ... trials management partner, Numoda Corporation (Numoda). One hundred ... January 2010. This investment follows and enhances the ...
... 24 Abbott ( NYSE: ABT ) today announced ... clinical trial to evaluate the safety and performance of ... second phase of the ABSORB clinical trial will enroll ... and New Zealand, and will incorporate device enhancements designed ...
Other Medicine Technology:DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 3DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 4DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 5Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial 2Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial 3Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial 4Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial 5
... one-of-kind Expander Sizer™ is ... problem of achieving the ... Expander Sizer™ zipper system ... to post procedure swelling ...
For lipoplasty of trochanteric region, abdomen, thighs, hips/flanks, buttocks & knees...
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
CDIs original garments with our exclusive Wonderfabric™....
Medicine Products: